The effect of discontinuing Aspirin at 34 and 36 weeks of pregnancy compared to term on the incidence of preeclampsia

The effect of discontinuing Aspirin at 34 and 36 weeks of pregnancy compared to term on the incidence of late-onset preeclampsia in pregnant women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190208042655N4

Enrollment

900

Registered

2025-03-17

Start date

2025-04-09

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group 1: Pregnant women will be prescribed 80 mg/daily Aspirin before 16 weeks of pregnancy, and Aspirin will be discontinued at 34 weeks of pregnancy. Intervention 2: Int

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: High-risk pregnant women for preeclampsia incidence according to NICE guideline Being at the age of 18 to 45 years

Exclusion criteria

Exclusion criteria: Aspirin consumption due to underlying disease The presence of any abnormalities in the fetus Unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Pre-eclampsia incidence. Timepoint: Once, after termination of pregnancy. Method of measurement: Diagnosis based on FMF guideline.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh Saedi

Tehran University of Medical Sciences

nsaedi@sina.tums.ac.ir+98 21 8608 9089

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026